Atea Pharmaceuticals, Inc.
AVIR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001593899
No open-market purchases or sales by Atea Pharmaceuticals, Inc. insiders were filed in the last 90 days; 124 institutions reported holding it in 13F filings for Q2 2026, worth $276.4M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Atea Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Atea Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Berger Franklin M | Director | 536,097 | Jun 23, 2026 | 1 |
| Kirsch Arthur S | Director | – | Jun 23, 2026 | 1 |
| Duncan Barbara Gayle | Director | 92,350 | Jun 23, 2026 | 1 |
| Polsky Bruce | Director | 124,806 | Jun 23, 2026 | 1 |
| Murphy Polly A. | Director | 121,745 | Jun 23, 2026 | 2 |
| Lucidi Bruno | Director | 142,350 | Jun 23, 2026 | 1 |
| Adams Jerome M. | Director | 92,350 | Jun 23, 2026 | 1 |
| Berman Howard | Director | – | Jun 23, 2026 | 1 |
| Corcoran Andrea | See Remarks | 823,576 | Mar 13, 2026 | 2 |
| Sommadossi Jean-Pierre | President, CEO, and Chairman | 767,830 | Feb 3, 2026 | 1 |
| Foster Wayne | EVP, Chief Accounting Officer | 79,329 | Feb 3, 2026 | 1 |
| Horga Maria Arantxa | Chief Medical Officer | 96,086 | Feb 3, 2026 | 1 |
| Vavricka John | Chief Commercial Officer | 82,594 | Feb 3, 2026 | 1 |
| Hammond Janet MJ | Chief Development Officer | 127,665 | Feb 3, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 21, 2026 (view filing) | May 18 | 3 days | Murphy Polly A.Director | PPurchase | +6.10K | $4.17 | +$25.4K | +7.1%92.1K after | Amended |
| Jan 17, 2025 (view filing) | Jan 15-16 | 2 days | Berger Franklin MDirector | PPurchase | +25.0K | $3.26 | +$81.5K | +5.5%476.9K after | Amended2 lots |
| Dec 12, 2024 (view filing) | Dec 10 | 2 days | Berger Franklin MDirector | SSale | −359.6K | $2.85 | −$1.02M | −44.3%451.9K after | |
| Sep 19, 2024 (view filing) | Sep 17-19 | 2 days | Sommadossi Jean-PierrePresident, CEO, and Chairman | SSale | −58.0K | $4.04 | −$234.2K | −1.0%5.87M after | 3 lots10b5-1 |
| Jun 21, 2024 (view filing) | Jun 20 | 1 day | Polsky BruceDirector | SSale | −17.5K | $3.49 | −$61.2K | −21.1%65.6K after | |
| Jun 7, 2024 (view filing) | Jun 5 | 2 days | Sommadossi Jean-PierrePresident, CEO, and Chairman | SSale | −1.01K | $4.00 | −$4.02K | 0.0%5.92M after | 10b5-1 |
| Feb 2, 2024 (view filing) | Feb 1 | 1 day | Corcoran AndreaSee Remarks | SSale | −15.8K | $3.84 | −$60.8K | −2.3%670.2K after | |
| Feb 2, 2024 (view filing) | Feb 1 | 1 day | Sommadossi Jean-PierrePresident, CEO, and Chairman | SSale | −56.9K | $3.85 | −$219.1K | −32.8%116.6K after | 10b5-1 |
| Feb 2, 2024 (view filing) | Feb 1 | 1 day | Horga Maria ArantxaChief Medical Officer | SSale | −15.9K | $3.84 | −$60.9K | −38.2%25.7K after | |
| Feb 2, 2024 (view filing) | Feb 1 | 1 day | Foster WayneEVP, Chief Accounting Officer | SSale | −12.5K | $3.84 | −$47.9K | −37.4%20.9K after | |
| Feb 2, 2024 (view filing) | Feb 1 | 1 day | Vavricka JohnChief Commercial Officer | SSale | −11.8K | $3.84 | −$45.4K | −35.5%21.5K after | |
| Feb 2, 2024 (view filing) | Feb 1 | 1 day | Hammond Janet MJChief Development Officer | SSale | −14.0K | $3.84 | −$53.9K | −28.4%35.4K after | |
| Nov 15, 2022 (view filing) | Nov 11-14 | 4 days | Berger Franklin MDirector | SSale | −41.7K | $5.15 | −$214.7K | −5.1%778.4K after | 2 lots |
| Dec 21, 2021 (view filing) | Dec 20 | 1 day | Murphy Polly A.Director | PPurchase | +12.0K | $8.57 | +$102.8K | +106.2%23.3K after |